Intellia Therapeutics Inc Total Liabilities
Intellia Therapeutics Inc total liabilities. Based on the latest financial reports, Intellia Therapeutics Inc (NTLA) has total liabilities worth $170.73 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check NTLA asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Intellia Therapeutics Inc (2014–2025)
Total liabilities of Intellia Therapeutics Inc from 2014 to 2025. This chart illustrates how Intellia Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore NTLA long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Intellia Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Intellia Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Anhui Wanwei Updated High-tech Material Industry Co Ltd
SHG:600063
|
China | CN¥6.17 Billion |
|
PROG Holdings Inc
NYSE:PRG
|
USA | $1.27 Billion |
|
Maharashtra Scooters Limited
NSE:MAHSCOOTER
|
India | Rs42.37 Billion |
|
Kardigan, Inc. Common Stock
NASDAQ:KARD
|
USA | $106.26 Million |
|
MicroPort Scientific Corporation
F:MSK
|
Germany | €2.20 Billion |
|
Telecom Argentina SA ADR
NYSE:TEO
|
USA | $10.33 Trillion |
|
Cardinal Energy Ltd
TO:CJ
|
Canada | CA$463.32 Million |
|
Shanghai Milkground Food Tech Co Ltd
SHG:600882
|
China | CN¥4.05 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Intellia Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Intellia Therapeutics Inc total assets.
Liquidity & Leverage Metrics
Intellia Therapeutics Inc Total Liabilities Ratios Explained
Intellia Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Intellia Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Intellia Therapeutics Inc (2014–2025)
The table below shows the annual total liabilities of Intellia Therapeutics Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $170.73 Million | -46.49% |
| 2024-12-31 | $319.06 Million | +27.21% |
| 2023-12-31 | $250.81 Million | -11.85% |
| 2022-12-31 | $284.53 Million | +11.92% |
| 2021-12-31 | $254.22 Million | +70.33% |
| 2020-12-31 | $149.25 Million | +131.76% |
| 2019-12-31 | $64.40 Million | -7.20% |
| 2018-12-31 | $69.39 Million | -8.25% |
| 2017-12-31 | $75.64 Million | -15.14% |
| 2016-12-31 | $89.13 Million | +502.94% |
| 2015-12-31 | $14.78 Million | +372.60% |
| 2014-12-31 | $3.13 Million | -- |
About Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agree… Read more